These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31445732)

  • 21. Esophageal fistula after EUS-FNA in a patient treated with bevacizumab for non-small-cell lung cancer.
    Stigt JA; Boomsma MF; de Vos tot Nederveen Cappel WH
    J Thorac Oncol; 2013 Mar; 8(3):e25-6. PubMed ID: 23407564
    [No Abstract]   [Full Text] [Related]  

  • 22. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.
    Peng TR; Tsai FP; Wu TW
    Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
    Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB
    Lancet; 2016 Apr; 387(10027):1540-1550. PubMed ID: 26712084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer.
    Toschi L; Cappuzzo F; Jänne PA
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix150-5. PubMed ID: 17631569
    [No Abstract]   [Full Text] [Related]  

  • 25. Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices.
    Velcheti V; Chandwani S; Chen X; Pietanza MC; Piperdi B; Burke T
    Immunotherapy; 2019 Dec; 11(18):1541-1554. PubMed ID: 31774363
    [No Abstract]   [Full Text] [Related]  

  • 26. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):22-23. PubMed ID: 28118650
    [No Abstract]   [Full Text] [Related]  

  • 27. Pembrolizumab for the first-line treatment of non-small cell lung cancer.
    Ninomiya K; Hotta K
    Expert Opin Biol Ther; 2018 Oct; 18(10):1015-1021. PubMed ID: 30207786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
    Wang H; Zhang L; Liu W
    J Thorac Oncol; 2019 Jul; 14(7):e141-e143. PubMed ID: 31235036
    [No Abstract]   [Full Text] [Related]  

  • 29. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
    Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS
    J Thorac Oncol; 2019 May; 14(5):793-801. PubMed ID: 30711649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Not Available].
    Fabre E; Pécuchet N; Cadranel J
    Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
    Takahashi T; Tateishi A; Bychkov A; Fukuoka J
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab for the treatment of non-small cell lung cancer.
    Lim SH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Opin Biol Ther; 2016; 16(3):397-406. PubMed ID: 26800463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab shows promise in lung cancer.
    Cleghorn S
    Lancet Respir Med; 2015 Jun; 3(6):429. PubMed ID: 25935769
    [No Abstract]   [Full Text] [Related]  

  • 35. PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
    Miyawaki E; Murakami H; Mori K; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Takahashi T
    Jpn J Clin Oncol; 2020 May; 50(5):617-622. PubMed ID: 32211792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
    BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follicular psoriasis induced by pembrolizumab in a patient with advanced non-small-cell lung cancer.
    Scarfì F; Lacava R; Patrizi A; Tartari F; Ravaioli GM; Veronesi G; Lambertini M; Dika E
    Int J Dermatol; 2019 Aug; 58(8):e151-e152. PubMed ID: 30964199
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
    Liao W; Huang J; Hutton D; Li Q
    J Med Econ; 2019 Apr; 22(4):344-349. PubMed ID: 30646794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
    Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
    PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
    N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.